Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

Rob Brainin Named Executive Vice President and Chief Business Officer;
Bill Zondler Appointed Senior Vice President and Chief Information Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced key appointments that further strengthen its executive team and support the company’s global expansion. Rob Brainin will join the company as executive vice president and chief business officer and Bill Zondler has been appointed senior vice president and chief information officer. Both executives will report to Marc Stapley, Veracyte’s chief executive officer.

“I’m delighted that Rob and Bill will join Veracyte’s leadership team. Both executives are seasoned life sciences leaders with proven track records for building successful organizations in complex and dynamic environments,” said Mr. Stapley. “Rob will lead our biopharmaceutical partnerships, including leveraging opportunities from our recent and in-process acquisitions, as well as our strategic planning and business development. Bill will build out our global IT infrastructure, ensuring our ability to serve clinical customers and patients across our broad products and geographies. Ultimately, these leaders will help Veracyte execute on our powerful vision of improving outcomes for patients all over the world at every step of their journey.”

Rob Brainin brings more than 20 years of executive experience in life sciences and health care. He most recently served as chief executive officer of Genuity Science (formerly known as WuXi NextCode), a company focused on integrating clinical and molecular data to derive insights that accelerate drug discovery and development. Prior to that, he served as vice president and general manager of the Life Sciences and Applied Genomics Business at Illumina, Inc. and, before that, was vice president and general manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. Prior to that, Mr. Brainin served in a number of positions at Life Technologies, Inc. and its predecessor, Invitrogen, primarily leading large businesses that served customers in the academic, clinical and biopharmaceutical segments. Earlier in his career, he was a management consultant at McKinsey & Co. and has served as an adjunct professor at the University of San Diego School of Law. Mr. Brainin is a member of the board of directors of Champions Oncology and the Children’s Tumor Foundation. He received his B.A. in economics, with honors, from Emory University and his J.D., cum laude, from Harvard Law School.

Bill Zondler’s career spans more than 25 years in information technology, including over 20 years in clinical laboratories and the pharmaceutical, medical device, life sciences and biotechnology industries. Prior to joining Veracyte, he was the chief information officer at Biotheranostics, Inc., a healthcare provider in oncology with a focus on early-stage breast cancer and a part of Hologic, Inc. In this role, Mr. Zondler led the company’s digitization initiatives and advanced their cybersecurity processes. Prior to Biotheranostics, he was the full-time consulting CIO at Axovant Sciences, Inc., a clinical-stage pharmaceutical company in New York. Previously, Mr. Zondler was CIO at Millenium Health, LLC, a privately held clinical laboratory, and before that was vice president of information services and CIO at Prometheus Laboratories, Inc. Earlier in his career, he was vice president of information technologies and facilities at Sanford Burnham Prebys Medical Discovery Institute in San Diego.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, the Veracyte logo, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.